Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 178 publications
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 22, 2025
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 22, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade.
Journal: bioRxiv : the preprint server for biology
Published: September 05, 2025
What does BCL-2 do? From new molecular insights to the clinical implications.
Journal: Cell death and differentiation
Published: July 29, 2025
Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia.
Journal: bioRxiv : the preprint server for biology
Published: June 06, 2025
Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.
Journal: Cell death and differentiation
Published: March 17, 2025
Whole-genome doubling drives immune evasion by silencing antigen presentation.
Journal: Cancer cell
Published: February 10, 2025
Conventional chemotherapy: millions of cures, unresolved therapeutic index.
Journal: Nature reviews. Cancer
Published: November 15, 2024
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.
Journal: Leukemia
Published: October 08, 2024
Last Updated: 09/26/2026